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Introduction
Study design plays an important role in the quali-
ty, execution, and interpretation of biomedical and 
public health research (1-12). Each study design 
has their own inherent strengths and weaknesses, 
and there can be a general hierarchy in study de-
signs, however, any hierarchy cannot be applied 
uniformly across study design types (3,5,6,9). Epi-
demiological and interventional research studies 
include three elements; 1) definition and measure 
of exposure in two or more groups, 2) measure of 
health outcome(s) in these same groups, and 3) 
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Abstract
The appropriate choice in study design is essential for the successful execution of biomedical and public health research. There are many study desi-
gns to choose from within two broad categories of observational and interventional studies. Each design has its own strengths and weaknesses, and 
the need to understand these limitations is necessary to arrive at correct study conclusions.
Observational study designs, also called epidemiologic study designs, are often retrospective and are used to assess potential causation in expo-
sure-outcome relationships and therefore influence preventive methods. Observational study designs include ecological designs, cross sectional, 
case-control, case-crossover, retrospective and prospective cohorts. An important subset of observational studies is diagnostic study designs, which 
evaluate the accuracy of diagnostic procedures and tests as compared to other diagnostic measures. These include diagnostic accuracy designs, dia-
gnostic cohort designs, and diagnostic randomized controlled trials.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease. 
Each study design has specific outcome measures that rely on the type and quality of data utilized. Additionally, each study design has potential li-
mitations that are more severe and need to be addressed in the design phase of the study. This manuscript is meant to provide an overview of study 
design types, strengths and weaknesses of common observational and interventional study designs.
Key words: study design; epidemiology; observational study; randomized trials; study strengths and weaknesses
statistical comparison made between groups to 
assess potential relationships between the expo-
sure and outcome, all of which are defined by the 
researcher (1-4,8,13). The measure of exposure in 
epidemiologic studies may be tobacco use (“Yes” 
vs. “No”) to define the two groups and may be the 
treatment (Active drug vs. placebo) in interven-
tional studies. Health outcome(s) can be the devel-
opment of a disease or symptom (e.g. lung cancer) 
or curing a disease or symptom (e.g. reduction of 
pain). Descriptive studies, which are not epidemio-
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logical or interventional, lack one or more of these 
elements and have limited application. High quali-
ty epidemiological and interventional studies con-
tain detailed information on the design, execution 
and interpretation of results, with methodology 
clearly written and able to be reproduced by other 
researchers.
Research is generally considered as primary or sec-
ondary research. Primary research relies upon data 
gathered from original research expressly for that 
purpose (1,3,5). Secondary research focuses on sin-
gle or multiple data sources that are not collected 
for a single research purpose (14,15). Secondary re-
search includes meta-analyses and best practice 
guidelines for treatments. This paper will focus on 
the study designs and their strengths, weaknesses, 
and common statistical outcomes of primary re-
search.
The choice of a study design hinges on many fac-
tors, including prior research, availability of study 
participants, funding, and time constraints. One 
common decision point is the desire to suggest 
causation. The most common causation criteria 
are proposed by Hill (16). Of these, demonstrating 
temporality is the only mandatory criterion for 
suggesting temporality. Therefore, prospective 
studies that follow study participants forward 
through time, including prospective cohort stud-
ies and interventional studies, are best suited for 
suggesting causation. Causal conclusions cannot 
be proven from an observational study. Addition-
ally, causation between an exposure and an out-
come cannot be proven by one study alone; multi-
ple studies across different populations should be 
considered when making causation assessments (17).
Primary research has been categorized in different 
ways. Common categorization schema include 
temporal nature of the study design (retrospective 
or prospective), usability of the study results (basic 
or applied), investigative purpose (descriptive or 
analytical), purpose (prevention, diagnosis or treat-
ment), or role of the investigator (observational or 
interventional). This manuscript categorizes study 
designs by observational and interventional crite-
ria, however, other categorization methods are de-
scribed as well.
Observational and interventional studies
Within primary research there are observational 
studies and interventional studies. Observational 
studies, also called epidemiological studies, are 
those where the investigator is not acting upon 
study participants, but instead observing natural 
relationships between factors and outcomes. Di-
agnostic studies are classified as observational 
studies, but are a unique category and will be dis-
cussed independently. Interventional studies, also 
called experimental studies, are those where the 
researcher intercedes as part of the study design. 
Additionally, study designs may be classified by 
the role that time plays in the data collection, ei-
ther retrospective or prospective. Retrospective 
studies are those where data are collected from 
the past, either through records created at that 
time or by asking participants to remember their 
exposures or outcomes. Retrospective studies can-
not demonstrate temporality as easily and are 
more prone to different biases, particularly recall 
bias. Prospective studies follow participants for-
ward through time, collecting data in the process. 
Prospective studies are less prone to some types 
of bias and can more easily demonstrate that the 
exposure preceded the disease, thereby more 
strongly suggesting causation. Table 1 describes 
the broad categories of observational studies: the 
disease measures applicable to each, the appropri-
ate measures of risk, and temporality of each study 
design. Epidemiologic measures include point 
prevalence, the proportion of participants with 
disease at a given point in time, period prevalence, 
the proportion of participants with disease within 
a specified time frame, and incidence, the accumu-
lation of new cases over time. Measures of risk are 
generally categorized into two categories: those 
that only demonstrate an association, such as an 
odds ratio (and some other measures), and those 
that demonstrate temporality and therefore sug-
gest causation, such as hazard ratio. Table 2 out-
lines the strengths and weaknesses of each obser-
vational study design.
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Study design Measures of disease Measures of risk Temporality
Ecological Prevalence (rough estimate) Prevalence ratio Retrospective
Proportional mortality Proportional mortalityStandardized mortality
Proportional mortality ratio
Standardized mortality ratio Retrospective
Case-crossover None Odds ratio Retrospective






















Both retrospective and 
prospective
Prospective only




Easy to assign exposure levels
Inaccuracy of data
Inability to control for confounders





Outcome (death) well captured
Utilize deaths only
Inaccuracy of data (death certificates)
Inability to control for confounders
Case-crossover
Reduces some types of bias
Good for acute health outcomes with a 
defined exposure
Cases act as their own control
Selection of comparison time point difficult
Challenging to execute






Ability to control for multiple 
confounders
Can assess multiple outcomes
No temporality
Not good for rare diseases






Ability to control for multiple 
confounders
Good for rare diseases
Can assess multiple exposures
Cannot calculate prevalence
Can only assess one outcome
Poor selection of controls can introduce bias
May be difficult to identify enough cases






Ability to control for multiple 
confounders
Can assess multiple exposures
Can assess multiple outcomes
Expensive
Time intensive
Not good for rare diseases
Table 1. Observational study design measures of disease, measures of risk, and temporality.
Table 2. Observational study design strengths and weaknesses.
Biochemia Medica 2014;24(2):199–210  http://dx.doi.org/10.11613/BM.2014.022 
202
Thiese MS. Study design types: an overview
Observational studies
Ecological study design
The most basic observational study is an ecologi-
cal study. This study design compares clusters of 
people, usually grouped based on their geograph-
ical location or temporal associations (1,2,6,9). Eco-
logical studies assign one exposure level for each 
distinct group and can provide a rough estimation 
of prevalence of disease within a population. Eco-
logical studies are generally retrospective. An ex-
ample of an ecological study is the comparison of 
the prevalence of obesity in the United States and 
France. The geographic area is considered the ex-
posure and the outcome is obesity. There are in-
herent potential weaknesses with this approach, 
including loss of data resolution and potential mis-
classification (10,11,13,18,19). This type of study de-
sign also has additional weaknesses. Typically 
these studies derive their data from large databas-
es that are created for purposes other than re-
search, which may introduce error or misclassifica-
tion (10,11). Quantification of both the number of 
cases and the total population can be difficult, 
leading to error or bias. Lastly, due to the limited 
amount of data available, it is difficult to control 
for other factors that may mask or falsely suggest 
a relationship between the exposure and the out-
come. However, ecological studies are generally 
very cost effective and are a starting point for hy-
pothesis generation.
Proportional mortality ratio study design
Proportional mortality ratio studies (PMR) utilize 
the defined well recorded outcome of death and 
subsequent records that are maintained regarding 
the decedent (1,6,8,20). By using records, this study 
design is able to identify potential relationships 
between exposures, such as geographic location, 
occupation, or age and cause of death. The epide-
miological outcomes of this study design are pro-
portional mortality ratio and standardized mortal-
ity ratio. In general these are the ratio of the pro-
portion of cause-specific deaths out of all deaths 
between exposure categories (20). As an example, 
these studies can address questions about higher 
proportion of cardiovascular deaths among differ-
ent ethnic and racial groups (21). A significant 
drawback to the PMR study design is that these 
studies are limited to death as an outcome (3,5,22). 
Additionally, the reliance on death records makes 
it difficult to control for individual confounding 
factors, variables that either conceal or falsely 
demonstrate associations between the exposure 
and outcome. An example of a confounder is to-
bacco use confounding the relationship between 
coffee intake and cardiovascular disease. Histori-
cally people often smoked and drank coffee while 
on coffee breaks. If researchers ignore smoking 
they would inaccurately find a strong relationship 
between coffee use and cardiovascular disease, 
where some of the risk is actually due to smoking. 
There are also concerns regarding the accuracy of 
death certificate data. Strengths of the study de-
sign include the well-defined outcome of death, 
the relative ease and low cost of obtaining data, 
and the uniformity of collection of these data 
across different geographical areas.
Cross-sectional study design
Cross-sectional studies are also called prevalence 
studies because one of the main measures availa-
ble is study population prevalence (1-12). These 
studies consist of assessing a population, as repre-
sented by the study sample, at a single point in 
time. A common cross-sectional study type is the 
diagnostic accuracy study, which is discussed later. 
Cross-sectional study samples are selected based 
on their exposure status, without regard for their 
outcome status. Outcome status is obtained after 
participants are enrolled. Ideally, a wider distribu-
tion of exposure will allow for a higher likelihood 
of finding an association between the exposure 
and outcome if one exists (1-3,5,8). Cross-sectional 
studies are retrospective in nature. An example of 
a cross-sectional study would be enrolling partici-
pants who are either current smokers or never 
smokers, and assessing whether or not they have 
respiratory deficiencies. Random sampling of the 
population being assessed is more important in 
cross-sectional studies as compared to other ob-
servational study designs. Selection bias from non-
random sampling may result in flawed measure of 
prevalence and calculation of risk. The study sam-
ple is assessed for both exposure and outcome at 
a single point in time. Because both exposure and 
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outcome are assessed at the same time, temporal-
ity cannot be demonstrated, i.e. it cannot be dem-
onstrated that the exposure preceded the disease 
(1-3,5,8). Point prevalence and period prevalence 
can be calculated in cross-sectional studies. Meas-
ures of risk for the exposure-outcome relationship 
that can be calculated in cross-sectional study de-
sign are odds ratio, prevalence odds ratio, preva-
lence ratio, and prevalence difference. Cross-sec-
tional studies are relatively inexpensive and have 
data collected on an individual which allows for 
more complete control for confounding. Addition-
ally, cross-sectional studies allow for multiple out-
comes to be assessed simultaneously.
Case-control study design
Case-control studies were traditionally referred to 
as retrospective studies, due to the nature of the 
study design and execution (1-12,23,24). In this 
study design, researchers identify study partici-
pants based on their case status, i.e. diseased or 
not diseased. Quantification of the number of indi-
viduals among the cases and the controls who are 
exposed allow for statistical associations between 
exposure and outcomes to be established (1-3,5,8). 
An example of a case control study is analysing the 
relationship between obesity and knee replace-
ment surgery. Cases are participants who have had 
knee surgery, and controls are a random sampling 
of those who have not, and the comparison is the 
relative odds of being obese if you have knee sur-
gery as compared to those that do not. Matching 
on one or more potential confounders allows for 
minimization of those factors as potential con-
founders in the exposure-outcome relationship 
(1-3,5,8). Additionally, case-control studies are at 
increased risk for bias, particularly recall bias, due 
to the known case status of study participants 
(1-3,5,8). Other points of consideration that have 
specific weight in case-control studies include the 
appropriate selection of controls that balance gen-
eralizability and minimize bias, the minimization 
of survivor bias, and the potential for length time 
bias (25). The largest strength of case-control stud-
ies is that this study design is the most efficient 
study design for rare diseases. Additional strengths 
include low cost, relatively fast execution com-
pared to cohort studies, the ability to collect indi-
vidual participant specific data, the ability to con-
trol for multiple confounders, and the ability to as-
sess multiple exposures of interest. The measure 
of risk that is calculated in case-control studies is 
the odds ratio, which are the odds of having the 
exposure if you have the disease. Other measures 
of risk are not applicable to case-control studies. 
Any measure of prevalence and associated meas-
ures, such as prevalence odds ratio, in a case-con-
trol study is artificial because the researcher arbi-
trarily sets the proportion of cases to non-cases in 
this study design. Temporality can be suggested, 
however, it is rarely definitively demonstrated be-
cause it is unknown if the development of the dis-
ease truly preceded the exposure. It should be 
noted that for certain outcomes, particularly death, 
the criteria for demonstrating temporality in that 
specific exposure-outcome relationship are met 
and the use of relative risk as a measure of risk may 
be justified.
Case-crossover study design
A case-crossover study relies upon an individual to 
act as their own control for comparison issues, 
thereby minimizing some potential confounders 
(1,5,12). This study design should not be confused 
with a crossover study design which is an interven-
tional study type and is described below. For case-
crossover studies, cases are assessed for their ex-
posure status immediately prior to the time they 
became a case, and then compared to their own 
exposure at a prior point where they didn’t be-
come a case. The selection of the prior point for 
comparison issues is often chosen at random or 
relies upon a mean measure of exposure over time. 
Case-crossover studies are always retrospective. 
An example of a case-crossover study would be 
evaluating the exposure of talking on a cell phone 
and being involved in an automobile crash. Cases 
are drivers involved in a crash and the comparison 
is that same driver at a random timeframe where 
they were not involved in a crash. These types of 
studies are particularly good for exposure-out-
come relationships where the outcome is acute 
and well defined, e.g. electrocutions, lacerations, 
automobile crashes, etc. (1,5). Exposure-outcome 
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relationships that are assessed using case-crosso-
ver designs should have health outcomes that do 
not have a subclinical or undiagnosed period prior 
to becoming a “case” in the study (12). The expo-
sure is cell phone use during the exposure periods, 
both before the crash and during the control peri-
od. Additionally, the reliance upon prior exposure 
time requires that the exposure not have an addi-
tive or cumulative effect over time (1,5). Case-
crossover study designs are at higher risk for hav-
ing recall bias as compared with other study de-
signs (12). Study participants are more likely to re-
member an exposure prior to becoming a case, as 
compared to not becoming a case.
Retrospective and prospective cohort study 
design
Cohort studies involve identifying study partici-
pants based on their exposure status and either 
following them through time to identify which 
participants develop the outcome(s) of interest, or 
look back at data that were created in the past, pri-
or to the development of the outcome. Prospec-
tive cohort studies are considered the gold stand-
ard of observational research (1-3,5,8,10,11). These 
studies begin with a cross-sectional study to cate-
gorize exposure and identify cases at baseline. Dis-
ease-free participants are then followed and cases 
are measured as they develop. Retrospective co-
hort studies also begin with a cross-sectional study 
to categorize exposure and identify cases. Expo-
sures are then measured based on records created 
at that time. Additionally, in an ideal retrospective 
cohort, case status is also tracked using historical 
data that were created at that point in time. Occu-
pational groups, particularly those that have regu-
lar surveillance or certifications such as Commer-
cial Truck Drivers, are particularly well positioned 
for retrospective cohort studies because records 
of both exposure and outcome are created as part 
of commercial and regulatory purposes (8). These 
types of studies have the ability to demonstrate 
temporality and therefore identify true risk factors, 
not associated factors, as can be done in other 
types of studies.
Cohort studies are the only observational study 
that can calculate incidence, both cumulative inci-
dence and an incidence rate (1,3,5,6,10,11). Also, 
because the inception of a cohort study is identi-
cal to a cross-sectional study, both point preva-
lence and period prevalence can be calculated. 
There are many measures of risk that can be calcu-
lated from cohort study data. Again, the measures 
of risk for the exposure-outcome relationship that 
can be calculated in cross-sectional study design 
of odds ratio, prevalence odds ratio, prevalence ra-
tio, and prevalence difference can be calculated in 
cohort studies as well. Measures of risk that lever-
age a cohort study’s ability to calculate incidence 
include incidence rate ratio, relative risk, risk ratio, 
and hazard ratio. These measures that demon-
strate temporality are considered stronger meas-
ures for demonstrating causation and identifica-
tion of risk factors.
Diagnostic testing and evaluation study de-
signs
A specific study design is the diagnostic accuracy 
study, which is often used as part of the clinical de-
cision making process. Diagnostic accuracy study 
designs are those that compare a new diagnostic 
method with the current “gold standard” diagnos-
tic procedure in a cross-section of both diseased 
and healthy study participants. Gold standard di-
agnostic procedures are the current best-practice 
for diagnosing a disease. An example is comparing 
a new rapid test for a cancer with the gold stand-
ard method of biopsy. There are many intricacies 
to diagnostic testing study designs that should be 
considered. The proper selection of the gold 
standard evaluation is important for defining the 
true measures of accuracy for the new diagnostic 
procedure. Evaluations of diagnostic test results 
should be blinded to the case status of the partici-
pant. Similar to the intention-to-treat concept dis-
cussed later in interventional studies, diagnostic 
tests have a procedure of analyses called intention 
to diagnose (ITD), where participants are analysed 
in the diagnostic category they were assigned, re-
gardless of the process in which a diagnosis was 
obtained. Performing analyses according to an a 
priori defined protocol, called per protocol analy-
ses (PP or PPA), is another potential strength to di-
agnostic study testing. Many measures of the new 
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diagnostic procedure, including accuracy, sensitiv-
ity, specificity, positive predictive value, negative 
predictive value, positive likelihood ratio, negative 
likelihood ratio, and diagnostic odds ratio can be 
calculated. These measures of the diagnostic test 
allow for comparison with other diagnostic tests 
and aid the clinician in determining which test to 
utilize.
Interventional study designs
Interventional study designs, also called experi-
mental study designs, are those where the re-
searcher intervenes at some point throughout the 
study. The most common and strongest interven-
tional study design is a randomized controlled tri-
al, however, there are other interventional study 
designs, including pre-post study design, non-ran-
domized controlled trials, and quasi-experiments 
(1,5,13). Experimental studies are used to evaluate 
study questions related to either therapeutic 
agents or prevention. Therapeutic agents can in-
clude prophylactic agents, treatments, surgical ap-
proaches, or diagnostic tests. Prevention can in-
clude changes to protective equipment, engineer-
ing controls, management, policy or any element 
that should be evaluated as to a potential cause of 
disease or injury.
Pre-post study design
A pre-post study measures the occurrence of an 
outcome before and again after a particular inter-
vention is implemented. A good example is com-
paring deaths from motor vehicle crashes before 
and after the enforcement of a seat-belt law. Pre-
post studies may be single arm, one group meas-
ured before the intervention and again after the 
intervention, or multiple arms, where there is a 
comparison between groups. Often there is an 
arm where there is no intervention. The no-inter-
vention arm acts as the control group in a multi-
arm pre-post study. These studies have the 
strength of temporality to be able to suggest that 
the outcome is impacted by the intervention, how-
ever, pre-post studies do not have control over 
other elements that are also changing at the same 
time as the intervention is implemented. There-
fore, changes in disease occurrence during the 
study period cannot be fully attributed to the spe-
cific intervention. Outcomes measured for pre-
post intervention studies may be binary health 
outcomes such as incidence or prevalence, or 
mean values of a continuous outcome such as 
systolic blood pressure may also be used. The ana-
lytic methods of pre-post studies depend on the 
outcome being measured. If there are multiple 
treatment arms, it is also likely that the difference 
from beginning to end within each treatment arm 
are analysed.
Non-randomized trial study design
Non-randomized trials are interventional study de-
signs that compare a group where an intervention 
was performed with a group where there was no 
intervention. These are convenient study designs 
that are most often performed prospectively and 
can suggest possible relationships between the in-
tervention and the outcome. However, these study 
designs are often subject to many types of bias 
and error and are not considered a strong study 
design.
Randomized controlled trial study design
Randomized controlled trials (RCTs) are the most 
common type of interventional study, and can 
have many modifications (26-28). These trials take 
a homogenous group of study participants and 
randomly divide them into two separate groups. If 
the randomization is successful then these two 
groups should be the same in all respects, both 
measured confounders and unmeasured factors. 
The intervention is then implemented in one 
group and not the other and comparisons of inter-
vention efficacy between the two groups are ana-
lysed. Theoretically, the only difference between 
the two groups through the entire study is the in-
tervention. An excellent example is the interven-
tion of a new medication to treat a specific disease 
among a group of patients. This randomization 
process is arguably the largest strength of an RCT 
(26-28). Additional methodological elements are 
utilized among RCTs to further strengthen the 
causal implication of the intervention’s impact. 
These include allocation concealment, blinding, 
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measuring compliance, controlling for co-inter-
ventions, measuring dropout, analysing results by 
intention to treat, and assessing each treatment 
arm at the same time point in the same manner.
Crossover randomized controlled trial study 
design
A crossover RCT is a type of interventional study 
design where study participants intentionally 
“crossover” to the other treatment arm. This should 
not be confused with the observational case-
crossover design. A crossover RCT begins the same 
as a traditional RCT, however, after the end of the 
first treatment phase, each participant is re-allo-
cated to the other treatment arm. There is often a 
wash-out period in between treatment periods. 
This design has many strengths, including demon-
strating reversibility, compensating for unsuccess-
ful randomization, and improving study efficiency 
by not using time to recruit subjects.
Allocation concealment theoretically guarantees 
that the implementation of the randomization is 
free from bias. This is done by ensuring that the 
randomization scheme is concealed from all indi-
viduals involved (26-30). A third party who is not 
involved in the treatment or assessment of the trial 
creates the randomization schema and study par-
ticipants are randomized according to that sche-
ma. By concealing the schema, there is a minimiza-
tion of potential deviation from that randomiza-
tion, either consciously or otherwise by the partici-
pant, researcher, provider, or assessor. The tradi-
tional method of allocation concealment relies 
upon sequentially numbered opaque envelopes 
with the treatment allocation inside. These enve-
lopes are generated before the study begins using 
the selected randomization scheme. Participants 
are then allocated to the specific intervention arm 
in the pre-determined order dictated by the sche-
ma. If allocation concealment is not utilized, there 
is the possibility of selective enrolment into an in-
tervention arm, potentially with the outcome of 
biased results.
Blinding in an RCT is withholding the treatment 
arm from individuals involved in the study. This 
can be done through use of placebo pills, deacti-
vated treatment modalities, or sham therapy. 
Sham therapy is a comparison procedure or treat-
ment which is identical to the investigational inter-
vention except it omits a key therapeutic element, 
thus rendering the treatment ineffective. An ex-
ample is a sham cortisone injection, where saline 
solution of the same volume is injected instead of 
cortisone. This helps ensure that patients do not 
know if they are receiving the active or control 
treatment. The process of blinding is utilized to 
help ensure equal treatment of the different 
groups, therefore continuing to isolate the differ-
ence in outcome between groups to only the in-
tervention being administered (28-31). Blinding 
within an RCT includes patient blinding, provider 
blinding, or assessor blinding. In some situations it 
is difficult or impossible to blind one or more of 
the parties involved, but an ideal study would have 
all parties blinded until the end of the study (26-
28,31,32).
Compliance is the degree of how well study par-
ticipants adhere to the prescribed intervention. 
Compliance or non-compliance to the interven-
tion can have a significant impact on the results of 
the study (26-29). If there is a differentiation in the 
compliance between intervention arms, that dif-
ferential can mask true differences, or erroneously 
conclude that there are differences between the 
groups when one does not exist. The measure-
ment of compliance in studies addresses the po-
tential for differences observed in intervention 
arms due to intervention adherence, and can allow 
for partial control of differences either through 
post hoc stratification or statistical adjustment.
Co-interventions, interventions that impact the 
outcome other than the primary intervention of 
the study, can also allow for erroneous conclusions 
in clinical trials (26-28). If there are differences be-
tween treatment arms in the amount or type of 
additional therapeutic elements then the study 
conclusions may be incorrect (29). For example, if a 
placebo treatment arm utilizes more over-the-
counter medication than the experimental treat-
ment arm, both treatment arms may have the 
same therapeutic improvement and show no ef-
fect of the experimental treatment. However, the 
placebo arm improvement is due to the over-the-
counter medication and if that was prohibited, 
http://dx.doi.org/10.11613/BM.2014.022 Biochemia Medica 2014;24(2):199–210 
  207
Thiese MS. Study design types: an overview
there may be a therapeutic difference between 
the two treatment arms. The exclusion or tracking 
and statistical adjustment of co-interventions 
serves to strengthen an RCT by minimizing this 
potential effect.
Participants drop out of a study for multiple rea-
sons, but if there are differential dropout rates be-
tween intervention arms or high overall dropout 
rates, there may be biased data or erroneous study 
conclusions (26-28). A commonly accepted drop-
out rate is 20% however, studies with dropout 
rates below 20% may have erroneous conclusions 
(29). Common methods for minimizing dropout in-
clude incentivizing study participation or short 
study duration, however, these may also lead to 
lack of generalizability or validity.
Intention-to-treat (ITT) analysis is a method of 
analysis that quantitatively addresses deviations 
from random allocation (26-28). This method anal-
yses individuals based on their allocated interven-
tion, regardless of whether or not that intervention 
was actually received due to protocol deviations, 
compliance concerns or subsequent withdrawal. 
By maintaining individuals in their allocated inter-
vention for analyses, the benefits of randomization 
will be captured (18,26-29). If analysis of actual 
treatment is solely relied upon, then some of the 
theoretical benefits of randomization may be lost. 
This analysis method relies on complete data. 
There are different approaches regarding the han-
dling of missing data and no consensus has been 
put forth in the literature. Common approaches 
are imputation or carrying forward the last ob-
served data from individuals to address issues of 
missing data (18,19).
Assessment timing can play an important role in 
the impact of interventions, particularly if inter-
vention effects are acute and short lived (26-29,33). 
The specific timing of assessments are unique to 
each intervention, however, studies that allow for 
meaningfully different timing of assessments are 
subject to erroneous results. For example, if as-
sessments occur differentially after an injection of 
a particularly fast acting, short-lived medication 
the difference observed between intervention 
arms may be due to a higher proportion of partici-
pants in one intervention arm being assessed 
hours after the intervention instead of minutes. By 
tracking differences in assessment times, research-
ers can address the potential scope of this prob-
lem, and try to address it using statistical or other 
methods (26-28,33).
Randomized controlled trials are the principle 
method for improving treatment of disease, and 
there are some standardized methods for grading 
RCTs, and subsequently creating best practice 
guidelines (29,34-36). Much of the current practice 
of medicine lacks moderate or high quality RCTs to 
address what treatment methods have demon-
strated efficacy and much of the best practice 
guidelines remains based on consensus from ex-
perts (28,37). The reliance on high quality method-
ology in all types of studies will allow for contin-
ued improvement in the assessment of causal fac-
tors for health outcomes and the treatment of dis-
eases.
Standards of research and reporting
There are many published standards for the de-
sign, execution and reporting of biomedical re-
search, which can be found in Table 3. The purpose 
and content of these standards and guidelines are 
to improve the quality of biomedical research 
which will result in providing sound conclusions to 
base medical decision making upon. There are 
published standards for categories of study de-
signs such as observational studies (e.g. STROBE), 
interventional studies (e.g. CONSORT), diagnostic 
studies (e.g. STARD, QUADAS), systematic reviews 
and meta-analyses (e.g. PRISMA), as well as others. 
The aim of these standards and guideline are to 
systematize and elevate the quality of biomedical 
research design, execution, and reporting.
Consolidated Standards Of Reporting Trials•	  
(CONSORT, www.consort-statement.org) are inter-
ventional study standards, a 25 item checklist 
and flowchart specifically designed for RCTs to 
standardize reporting of key elements including 
design, analysis and interpretation of the RCT.
Strengthening the Reporting of Observa-•	
tional studies in Epidemiology (STROBE, 
www.strobe-statement.org) is a collection of 
guidelines specifically for standardization and 
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Standard name Acronym Website
Consolidated Standards Of Reporting Trials CONSORT www.consort-statement.org
Strengthening the Reporting of Observational studies in Epidemiology STROBE www.strobe-statement.org
Standards for Reporting Studies of Diagnostic Accuracy STARD www.stard-statement.org
Quality assessment of diagnostic accuracy studies QUADAS www.bris.ac.uk/quadas
Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA www.prisma-statement.org
Consolidated criteria for reporting qualitative research COREQ
Statistical Analyses and Methods in the Published Literature SAMPL
Consensus-based Clinical Case Reporting Guideline Development CARE www.care-statement.org/
Standards for Quality Improvement Reporting Excellence SQUIRE www.squire-statement.org
Consolidated Health Economic Evaluation Reporting Standards CHEERS www.ispor.org/taskforces/EconomicPubGuidelines.asp
Enhancing transparency in reporting the synthesis of qualitative research ENTREQ
Table 3. Published standard for study design and reporting.
improvement of the reporting of observational 
epidemiological research. There are specific 
subsets of the STROBE statement including mo-
lecular epidemiology (STROBE-ME), infectious 
diseases (STROBE-ID) and genetic association 
studies (STREGA).
Standards for Reporting Studies of Diagnos-•	
tic Accuracy (STARD, www.stard-statement.
org) is a 25 element checklist and flow diagram 
specifically designed for the reporting of diag-
nostic accuracy studies.
Quality assessment of diagnostic accuracy •	
studies (QUADAS, www.bris.ac.uk/quadas) is a 
quality assessment of diagnostic accuracy stud-
ies.
Preferred Reporting Items for Systematic •	
Reviews and Meta-Analyses (PRISMA, www.
prisma-statement.org) is a 27 element checklist 
and multiphase flow diagram to improve quali-
ty of reporting systematic reviews and meta-
analyses. It replaces the QUOROM statement.
Consolidated criteria for reporting qualita-•	
tive research (COREQ) is a 32 element checklist 
designed for reporting of qualitative data from 
interviews and focus groups.
Statistical Analyses and Methods in the Pub-•	
lished Literature (SAMPL) is a guideline for sta-
tistical methods and analyses of all types of bi-
omedical research.
Consensus-based Clinical Case Reporting •	
Guideline Development (CARE, www.care-
statement.org) is a checklist comprised of 13 el-
ements and is designed only for case reports.
Standards for Quality Improvement Report-•	
ing Excellence (SQUIRE, www.squire-state-
ment.org) are publication guidelines comprised 
of 19 elements, for authors aimed at quality im-
provement in health care reporting.
Consolidated Health Economic Evaluation •	
Reporting Standards (CHEERS) is a 24 element 
checklist of reporting practices for economic 
evaluations of interventional studies.
Enhancing transparency in reporting the •	
synthesis of qualitative research (ENTREQ) is 
a guideline specifically for standardizing and 
improving the reporting of qualitative biomedi-
cal research.
When designing or evaluating a study it may be 
helpful to review the applicable standards prior to 
executing and publishing the study. All published 
standards and guidelines are available on the web, 
and are updated based on current best practices 
as biomedical research evolves. Additionally, there 
is a network called “Enhancing the quality and 
transparency of health research” (EQUATOR, www.
equator-network.org), which has guidelines and 
checklists for all standards reported in table 3 and 
is continually updated with new study design or 
specialty specific standards.
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Conclusion
The appropriate selection of a study design is only 
one element in successful research. The selection 
of a study design should incorporate considera-
tion of costs, access to cases, identification of the 
exposure, the epidemiologic measures that are re-
quired, and the level of evidence that is currently 
published regarding the specific exposure-out-
come relationship that is being assessed. Review-
ing appropriate published standards when design-
ing a study can substantially strengthen the exe-
cution and interpretation of study results.
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